secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0000950170-23-006586
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics reports Q4 net loss of $18.7M; cash $120M funds operations into Q2 2024
--------------------------------------------------------------------------------

- Q4 2022 net loss $18.7M vs $14.2M in Q4 2021; FY2022 net loss $66.2M vs $48.6M.
- Q4 2022 revenue $3.1M, up from $2.9M; FY2022 revenue $13.5M (vs $10.1M in 2021).
- Cash and cash equivalents $120.0M as of Dec. 31, 2022; runway into Q2 2024.
- Phase 1 hematologic trial for TSC-100/101 expected to enroll all three arms by mid-2023 with preliminary safety/biomarker data.
- Solid tumor INDs for T-Plex and two TCRs cleared; initial single-agent TCR data expected by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017023006586/0000950170-23-006586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017023006586/tcrx-20230308.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer